Rapid Tophus Resolution in Chronic Refractory Gout Patients Treated with Pegloticase

被引：0
|
作者：
Mandell, Brian F. [1 ]
Baraf, Herbert S. B. [2 ]
Yeo, Anthony [3 ]
Lipsky, Peter E. [4 ]
机构：
[1] Cleveland Clin, Rheumatol, Cleveland, OH 44106 USA
[2] Ctr Rheumatol & Bone Res, Wheaton, MD USA
[3] Horizon Pharma, Lake Forest, IL USA
[4] AMPEL BioSolut LLC, Charlottesville, VA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2054
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
    Herbert SB Baraf
    Michael A Becker
    Sergio R Gutierrez-Urena
    Edward L Treadwell
    Janitzia Vazquez-Mellado
    Claudia D Rehrig
    Faith D Ottery
    John S Sundy
    Robert A Yood
    Arthritis Research & Therapy, 15
  • [22] Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout
    Saag, Kenneth
    Feinman, Mitchell
    Baraf, Herbert S. B.
    Fleischmann, Roy
    Kavanaugh, Arthur
    Lipsky, Peter E.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [23] Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
    Baraf, Herbert S. B.
    Becker, Michael A.
    Gutierrez-Urena, Sergio R.
    Treadwell, Edward L.
    Vazquez-Mellado, Janitzia
    Rehrig, Claudia D.
    Ottery, Faith D.
    Sundy, John S.
    Yood, Robert A.
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
  • [24] THE FREQUENCY OF FLARES IN SUBJECTS WITH CHRONIC REFRACTORY GOUT TREATED WITH PEGLOTICASE IS RELATED TO VARIATION IN THE LEVEL OF PLASMA URATE
    Calabrese, L.
    Fields, T.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 141 - 141
  • [25] Pegloticase (Krystexxa) for Treatment of Refractory Gout
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1357): : 9 - 10
  • [26] COMPANION IMMUNOSUPPRESSION WITH AZATHIOPRINE INCREASES THE FREQUENCY OF PERSISTENT RESPONSIVENESS TO PEGLOTICASE IN PATIENTS WITH CHRONIC REFRACTORY GOUT
    Rainey, H.
    Baraf, H. S. B.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 438 - 439
  • [27] FACTORS INFLUENCING TOPHUS RESOLUTION IN PATIENTS WITH PERSISTENT URATE LOWERING RESPONSES TO PEGLOTICASE
    Mandell, B.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1043 - 1043
  • [28] Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
    Lipsky, Peter
    Yeo, Anthony
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4102 - 4104
  • [29] Long-term safety of pegloticase in chronic gout refractory to conventional treatment
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) : 1469 - 1474
  • [30] Pegloticase: A guide to its use in treatment-refractory chronic gout in the EU
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2013, 29 (6) : 155 - 160
12345